Algernon Pharmaceuticals DMT Stroke Clinical Program
Join Christopher J. Moreau, CEO of Algernon Pharmaceuticals discuss repurposing DMT from its psychedelic effects to a new potential treatment for Stroke.
** Video Runtime: 1:54
Algernon's Clinical Research Programs
After over 40 years of dormancy, a new psychedelic revolution has emerged. At the nexus of this next-generation mystical revival, lies a molecule naturally produced abundantly throughout the plant and animal kingdoms, including humans. Regarded as the world’s most potent psychoactive compound by scientists and psychedelic explorers alike, Dimethyltryptamine (DMT) seems to be shifting the consciousness paradigm.
In the early 1990s, Dr. Rick Strassman conducted the first government-sanctioned, human psychedelic research with DMT. Strassman’s research serves as the narrative backbone for The Spirit Molecule.
While other research is exploring DMT for its hallucinogenic qualities and effects, Algernon will be working to unlock DMT’s non-psychedelic potential to help promote healing and recovery in the brain from a stroke, one of the most devastating injuries a human being can experience.